|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Logicbio Therapeutics, Inc. (LOGC) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
22,180,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile LogicBio Therapeutics is a clinical-stage genetic medicine company focused on genome editing and gene delivery platforms to address diseases from infancy through adulthood. Co.'s genome editing platform, GeneRide™, is an approach to gene insertion harnessing a cell's natural deoxyribonucleic acid repair process. Co.'s product candidate, LB-001, is a single-administration, genome editing therapy developed using its GeneRide technology for the treatment of methylmalonic acidemia in pediatric patients. Co.'s other product candidate, LB-401 is based on its GeneRide technology. LB-401 is a genome editing therapy being developed for the treatment of hereditary tyrosinemia type 1 in newborns.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Moscicki Richard A |
Director |
– • – |
2022-11-16 |
4 |
D |
$0.00 |
$0 |
D/D |
(3,916) |
0 |
|
- |
|
| Enyedy Mark J |
Director |
– • – |
2022-11-16 |
4 |
D |
$0.00 |
$0 |
D/D |
(2,921) |
0 |
|
- |
|
| Chen Leon |
Director |
– • – |
2022-11-16 |
4 |
D |
$0.00 |
$0 |
D/D |
(22,333) |
0 |
|
- |
|
| Chereau Frederic |
President, CEO |
• • – |
2022-11-16 |
4 |
D |
$0.00 |
$0 |
D/D |
(253,811) |
0 |
|
- |
|
| Gruskin Daniel |
Chief Medical Officer |
• – – |
2022-11-16 |
4 |
D |
$0.00 |
$0 |
D/D |
(3,331) |
0 |
|
- |
|
| Kay Mark A |
Director |
– • – |
2022-11-16 |
4 |
D |
$0.00 |
$0 |
D/D |
(784,557) |
0 |
|
- |
|
| Wyzga Michael S |
Director |
– • – |
2022-11-16 |
4 |
D |
$0.00 |
$0 |
D/D |
(3,141) |
0 |
|
- |
|
| Jones Cecilia |
Chief Financial Officer |
• – – |
2022-01-12 |
4 |
D |
$2.01 |
$4,372 |
D/D |
(2,175) |
3,764 |
|
- |
|
| Jones Cecilia |
Chief Financial Officer |
• – – |
2022-01-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,939 |
5,939 |
|
- |
|
| Gruskin Daniel |
Chief Medical Officer |
• – – |
2021-08-09 |
4 |
S |
$4.35 |
$6,381 |
D/D |
(1,467) |
3,331 |
|
- |
|
| Gruskin Daniel |
Chief Medical Officer |
• – – |
2021-08-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,798 |
4,798 |
|
- |
|
| Chiang Kyle |
Chief Operating Officer |
• – – |
2021-04-16 |
4 |
S |
$5.73 |
$17,058 |
D/D |
(2,977) |
23,387 |
|
- |
|
| Chereau Frederic |
President and Chief Executive |
• • – |
2021-04-16 |
4 |
S |
$5.73 |
$43,216 |
D/D |
(7,542) |
253,811 |
|
- |
|
| Chiang Kyle |
Chief Operating Officer |
• – – |
2021-04-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,360 |
26,364 |
|
- |
|
| Chereau Frederic |
President and Chief Executive |
• • – |
2021-04-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
23,414 |
261,353 |
|
- |
|
| Wyzga Michael S |
Director |
– • – |
2021-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,141 |
3,141 |
|
- |
|
| Kay Mark A |
Director |
– • – |
2021-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,199 |
2,199 |
|
- |
|
| Enyedy Mark J |
Director |
– • – |
2021-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,921 |
2,921 |
|
- |
|
| Chen Leon |
Director |
– • – |
2021-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,298 |
3,298 |
|
- |
|
| Moscicki Richard A |
Director |
– • – |
2021-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,916 |
3,916 |
|
- |
|
| Oconnell Daniel P |
Director |
– • – |
2020-12-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,513 |
2,513 |
|
- |
|
| Chiang Kyle |
Chief Operating OfficerOfficer |
• – – |
2020-11-02 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
17,004 |
|
- |
|
| Orbimed Genesis Gp Llc |
Director |
– • • |
2020-10-01 |
4 |
B |
$6.00 |
$8,888,892 |
I/I |
1,481,482 |
296,296 |
2.25 |
- |
|
| Chimovits Erez |
Director |
– • • |
2020-10-01 |
4 |
B |
$6.00 |
$8,888,892 |
I/I |
1,481,482 |
296,296 |
2.25 |
- |
|
| Arix Bioscience Holdings Ltd |
10% Owner |
– – • |
2020-09-28 |
4 |
S |
$7.54 |
$2,061,866 |
I/I |
(273,584) |
2,381,436 |
|
- |
|
47 Records found
|
|
Page 1 of 2 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
